• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection.SARS-CoV-2 感染后中和抗体和 T 细胞应答的持久性。
Front Med. 2020 Dec;14(6):746-751. doi: 10.1007/s11684-020-0822-5. Epub 2020 Oct 5.
2
SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.根据症状严重程度评估 SARS-CoV-2 特异性抗体和 T 细胞应答动力学。
Am J Trop Med Hyg. 2021 Jun 17;105(2):395-400. doi: 10.4269/ajtmh.20-1594.
3
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
4
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.接种灭活 SARS-CoV-2 疫苗后突破性病例的免疫特征和临床结局。
Front Immunol. 2021 Sep 29;12:742914. doi: 10.3389/fimmu.2021.742914. eCollection 2021.
5
Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.COVID-19 患者症状出现后七个月内 SARS-CoV-2 特异性和中和抗体的动力学。
Microbiol Spectr. 2021 Oct 31;9(2):e0059021. doi: 10.1128/Spectrum.00590-21. Epub 2021 Sep 22.
6
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.感染 SARS-CoV-2 一年后自然增强的对其的中和广度。
Nature. 2021 Jul;595(7867):426-431. doi: 10.1038/s41586-021-03696-9. Epub 2021 Jun 14.
7
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay.采用 ex vivo ELISpot assay 检测 COVID-19 恢复期患者和未接触者的 SARS-CoV-2 特异性 T 细胞免疫。
Clin Microbiol Infect. 2021 Jul;27(7):1029-1034. doi: 10.1016/j.cmi.2021.03.010. Epub 2021 Apr 2.
8
Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.巴西恢复期血浆中 SARS-CoV-2 抗体筛查:一项自愿恢复期供者计划的初步经验教训。
Transfusion. 2020 Dec;60(12):2938-2951. doi: 10.1111/trf.16065. Epub 2020 Sep 16.
9
Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.基于 COVID-19 患者队列的 SARS-CoV-2 抗体的长期动力学和灭活疫苗对 SARS-CoV-2 抗体的影响。
Front Immunol. 2022 Jan 27;13:829665. doi: 10.3389/fimmu.2022.829665. eCollection 2022.
10
Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.SARS-CoV-2 住院和社区患者的持久 T 细胞和体液反应。
PLoS One. 2022 Feb 22;17(2):e0261979. doi: 10.1371/journal.pone.0261979. eCollection 2022.

引用本文的文献

1
Persistence of SARS-CoV-2-IgG antibody durability in convalescent COVID-19 patients 6 months after the natural infection.新冠康复患者自然感染6个月后SARS-CoV-2-IgG抗体持久性
Front Med (Lausanne). 2025 Aug 11;12:1623509. doi: 10.3389/fmed.2025.1623509. eCollection 2025.
2
Multi-Antigen Viral-Vectored Vaccine Protects Against SARS-CoV-2 and Variants in a Lethal hACE2 Transgenic Mouse Model.多抗原病毒载体疫苗在致死性人血管紧张素转换酶2转基因小鼠模型中对严重急性呼吸综合征冠状病毒2及其变体具有保护作用。
Vaccines (Basel). 2025 Apr 15;13(4):411. doi: 10.3390/vaccines13040411.
3
Durability of Functional SARS-CoV-2-Specific Immunological Memory and T Cell Response up to 8-9 Months Postrecovery From COVID-19.新冠康复后长达8至9个月的SARS-CoV-2特异性功能性免疫记忆和T细胞反应的持久性
J Immunol Res. 2025 Feb 10;2025:9743866. doi: 10.1155/jimr/9743866. eCollection 2025.
4
Integrating Interpretability in Machine Learning and Deep Neural Networks: A Novel Approach to Feature Importance and Outlier Detection in COVID-19 Symptomatology and Vaccine Efficacy.将可解释性融入机器学习和深度神经网络:一种用于新冠症状学和疫苗效力中特征重要性及异常检测的新方法。
Viruses. 2024 Nov 29;16(12):1864. doi: 10.3390/v16121864.
5
Nonconserved epitopes dominate reverse preexisting T cell immunity in COVID-19 convalescents.非保守表位主导 COVID-19 恢复期患者的反向预先存在 T 细胞免疫。
Signal Transduct Target Ther. 2024 Jun 12;9(1):160. doi: 10.1038/s41392-024-01876-3.
6
Durability of immune responses to SARS-CoV-2 infection and vaccination.对新冠病毒感染和疫苗接种的免疫反应的持久性。
Semin Immunol. 2024 May;73:101884. doi: 10.1016/j.smim.2024.101884. Epub 2024 Jun 10.
7
Long-Term Follow-Up of COVID-19 Convalescents-Immune Response Associated with Reinfection Rate and Symptoms.COVID-19 康复者的长期随访——与再感染率和症状相关的免疫反应。
Viruses. 2023 Oct 17;15(10):2100. doi: 10.3390/v15102100.
8
Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland.中国大陆奥密克戎亚谱系多样性及2022年秋冬新冠疫情流行病学特征的初步评估
Front Med. 2023 Aug;17(4):758-767. doi: 10.1007/s11684-022-0981-7. Epub 2023 Mar 31.
9
Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai.2022 年春季上海 COVID-19 疫情期间,先前接种疫苗可预防奥密克戎 BA.2.2 亚系感染。
Front Med. 2023 Jun;17(3):562-575. doi: 10.1007/s11684-022-0977-3. Epub 2023 Mar 23.
10
Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology.用 BcfA 佐剂疫苗对小鼠进行初次加强免疫可诱导持续的黏膜免疫,预防 SARS-CoV-2 感染和发病。
J Immunol. 2023 May 1;210(9):1257-1271. doi: 10.4049/jimmunol.2200297.

本文引用的文献

1
A Thermostable mRNA Vaccine against COVID-19.一种针对 COVID-19 的耐热 mRNA 疫苗。
Cell. 2020 Sep 3;182(5):1271-1283.e16. doi: 10.1016/j.cell.2020.07.024. Epub 2020 Jul 23.
2
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
3
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.追踪 SARS-CoV-2 刺突蛋白的变化:D614G 增加 COVID-19 病毒感染力的证据。
Cell. 2020 Aug 20;182(4):812-827.e19. doi: 10.1016/j.cell.2020.06.043. Epub 2020 Jul 3.
4
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.COVID-19 和 SARS 病例以及未感染对照者的 SARS-CoV-2 特异性 T 细胞免疫。
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.
5
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.恢复期患者体内对 SARS-CoV-2 的趋同抗体反应
Nature. 2020 Aug;584(7821):437-442. doi: 10.1038/s41586-020-2456-9. Epub 2020 Jun 18.
6
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.在小动物模型中分离出有效的 SARS-CoV-2 中和抗体并预防疾病。
Science. 2020 Aug 21;369(6506):956-963. doi: 10.1126/science.abc7520. Epub 2020 Jun 15.
7
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
8
Viral and host factors related to the clinical outcome of COVID-19.与 COVID-19 临床结果相关的病毒和宿主因素。
Nature. 2020 Jul;583(7816):437-440. doi: 10.1038/s41586-020-2355-0. Epub 2020 May 20.
9
Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies.COVID-19 的研究进展:病毒、发病机制以及基于证据的防控和治疗策略。
Front Med. 2020 Apr;14(2):117-125. doi: 10.1007/s11684-020-0773-x. Epub 2020 Apr 21.
10
Coronavirus disease 2019 (COVID-19): a clinical update.新型冠状病毒病 2019(COVID-19):临床更新。
Front Med. 2020 Apr;14(2):126-135. doi: 10.1007/s11684-020-0767-8. Epub 2020 Apr 2.

SARS-CoV-2 感染后中和抗体和 T 细胞应答的持久性。

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection.

机构信息

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Shanghai Public Health Clinical Center, Shanghai, 201508, China.

出版信息

Front Med. 2020 Dec;14(6):746-751. doi: 10.1007/s11684-020-0822-5. Epub 2020 Oct 5.

DOI:10.1007/s11684-020-0822-5
PMID:33017040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7533664/
Abstract

The ongoing pandemic of Coronavirus disease 19 (COVID-19) is caused by a newly discovered β Coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How long the adaptive immunity triggered by SARS-CoV-2 can last is of critical clinical relevance in assessing the probability of second infection and efficacy of vaccination. Here we examined, using ELISA, the IgG antibodies in serum specimens collected from 17 COVID-19 patients at 6-7 months after diagnosis and the results were compared to those from cases investigated 2 weeks to 2 months post-infection. All samples were positive for IgGs against the S- and N-proteins of SARS-CoV-2. Notably, 14 samples available at 6-7 months post-infection all showed significant neutralizing activities in a pseudovirus assay, with no difference in blocking the cell-entry of the 614D and 614G variants of SARS-CoV-2. Furthermore, in 10 blood samples from cases at 6-7 months post-infection used for memory T-cell tests, we found that interferon γ-producing CD4 and CD8 cells were increased upon SARS-CoV-2 antigen stimulation. Together, these results indicate that durable anti-SARS-CoV-2 immunity is common in convalescent population, and vaccines developed from 614D variant may offer protection from the currently predominant 614D variant of SARS-CoV-2.

摘要

持续的 19 冠状病毒病(COVID-19)大流行是由一种新发现的β冠状病毒引起的,称为严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)。SARS-CoV-2 引发的适应性免疫能持续多久,对于评估二次感染的概率和疫苗的效果具有重要的临床意义。在这里,我们使用 ELISA 法检测了 17 例 COVID-19 患者在确诊后 6-7 个月采集的血清标本中的 IgG 抗体,并将结果与感染后 2 周到 2 个月时的病例进行了比较。所有样本均对 SARS-CoV-2 的 S 和 N 蛋白产生 IgG 抗体呈阳性。值得注意的是,在感染后 6-7 个月时,14 个样本在假病毒测定中均显示出显著的中和活性,对 SARS-CoV-2 的 614D 和 614G 变异体的细胞进入阻断无差异。此外,在 10 份感染后 6-7 个月的病例血液样本中,用于记忆 T 细胞测试,我们发现 SARS-CoV-2 抗原刺激后,产生干扰素 γ 的 CD4 和 CD8 细胞增加。综上所述,这些结果表明,在恢复期人群中普遍存在持久的抗 SARS-CoV-2 免疫,并且由 614D 变异体开发的疫苗可能提供针对目前主要的 SARS-CoV-2 614D 变异体的保护。